Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco‐epidemiological approach
暂无分享,去创建一个
A. Costa-Pereira | M. Cravo | J. Cotter | P. Lago | F. Magro | R. Gonçalves | J. Deus | I. Cremers | A. Vieira | P. Peixe | P. Caldeira | H. Lopes | J. Reis | L. Barros | P. Ministro | A. Duarte | M. Campos | L. Carvalho | L. Azevedo | F. Portela | M. Lurdes | R. Gonçalves | L. Azevedo | Lina Carvalho
[1] A. Costa-Pereira,et al. Ulcerative colitis in a Southern European country: A national perspective , 2010, Inflammatory bowel diseases.
[2] M. Cravo,et al. Crohn's disease in a southern European country: Montreal classification and clinical activity , 2009, Inflammatory bowel diseases.
[3] M. Cravo,et al. Inflammatory Bowel Disease: A Patient’s and Caregiver’s Perspective , 2009, Digestive Diseases and Sciences.
[4] A E Ades,et al. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. , 2008, Biostatistics.
[5] Catherine H Mercer,et al. Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data , 2008 .
[6] W. Bemelman,et al. European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .
[7] S. Hanauer,et al. Treatment of inflammatory bowel disease: a review of medical therapy. , 2008, World journal of gastroenterology.
[8] B. Feagan,et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.
[9] P. Lakatos. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.
[10] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[11] P. Lakatos,et al. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? , 2006, Postgraduate Medical Journal.
[12] R. Bergman,et al. Systematic review: the use of mesalazine in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.
[13] J. Cabrita,et al. Using a pharmacoepidemiological approach to estimate diabetes type 2 prevalence in Portugal , 2006, Pharmacoepidemiology and drug safety.
[14] A. Forbes,et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.
[15] Alex J. Sutton,et al. Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches , 2006 .
[16] M. Keisu,et al. Sulfasalazine associated agranulocytosis in Sweden 1972–1989 , 1992, European Journal of Clinical Pharmacology.
[17] Nicky J Welton,et al. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence , 2005 .
[18] V. Binder. Epidemiology of IBD during the twentieth century: an integrated view. , 2004, Best practice & research. Clinical gastroenterology.
[19] E. Loftus. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.
[20] D. Purdie. Statistical Methods in Medical Research, 4th edn , 2003 .
[21] M. Langman,et al. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.
[22] W. Sandborn,et al. Epidemiology of inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.
[23] P. J. Kelly,et al. Inflammatory bowel disease: epidemiology and management in an English general practice population , 2000, Alimentary pharmacology & therapeutics.
[24] R. Pounder,et al. Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort , 1998, BMJ.
[25] P. Munkholm. Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. , 1997, Danish medical bulletin.
[26] J. Lennard-jones,et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). , 1996, Gut.
[27] D. Palli,et al. A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). , 1996, Scandinavian journal of gastroenterology.
[28] R. Da Cas,et al. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome , 1996, Alimentary pharmacology & therapeutics.
[29] F. Sartor,et al. Results of an epidemiological study on drug-treated intraocular hypertension in Belgium. , 1996, Journal of clinical epidemiology.
[30] F. Sartor,et al. Estimate of disease prevalence using drug consumption data. , 1995, American journal of epidemiology.
[31] H. Jick,et al. The Risk of Sulfasalazine‐ and Mesalazine‐Associated Blood Disorders , 1995, Pharmacotherapy.
[32] G. Corrao,et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease , 1994, Alimentary pharmacology & therapeutics.
[33] D. Vicent,et al. Incidence and prevalence of ulcerative colitis and Crohn's disease in urban and rural areas of Spain from 1981 to 1988. , 1994, Journal of clinical gastroenterology.
[34] R. Modigliani,et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.
[35] C. Prantera,et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease , 1992 .
[36] V. Jureša,et al. Ulcerative colitis in Zagreb, Yugoslavia: incidence and prevalence 1980-1989. , 1991, International journal of epidemiology.
[37] S. Kreiner,et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. , 1991, Scandinavian journal of gastroenterology.
[38] V. Jureša,et al. Epidemiology of Crohn's disease in Zagreb, Yugoslavia: a ten-year prospective study. , 1991, International journal of epidemiology.
[39] A. Sonnenberg,et al. Geographic variation of inflammatory bowel disease within the United States. , 1991, Gastroenterology.
[40] M. Scheurlen,et al. Epidemiology of inflammatory bowel disease in the county of Tübingen (West Germany). , 1989, Scandinavian journal of gastroenterology. Supplement.
[41] J. Lennard-jones,et al. Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.
[42] H. Morgenstern,et al. Epidemiologic Research: Principles and Quantitative Methods. , 1983 .